Navigation Links
MiMedx To Present At 33rd Annual Canaccord Genuity Growth Conference
Date:8/5/2013

MARIETTA, Ga., Aug. 5, 2013 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 33rd Annual Canaccord Genuity Growth Conference in Boston.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on August 14th at 11:30 a.m. EDT at the InterContinental Boston.  A webcast of this presentation will be available on the Company's website, www.mimedx.com

About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 160,000 allografts to date
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Mimedx Scientific Study Is Electronically Published in The International Wound Journal
2. MiMedx Announces Record Second Quarter Results
3. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
4. MiMedx To Exceed High End Of Second Quarter Guidance
5. MiMedx to Ring NASDAQ Stock Market Opening Bell
6. MiMedx to Present at Jefferies 2013 Global Healthcare Conference
7. MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
8. MiMedx Announces Record First Quarter 2013 Results
9. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
10. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
11. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014   Synthetic Biologics, Inc. (NYSE MKT: ... serious infections and diseases, announced today that the U.S. ... Allowance for a composition of matter patent application that ... program, SYN-004. This is Synthetic Biologics, first allowed patent ... adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... SAN DIEGO, Nov. 2 Cardium Therapeutics (NYSE Amex: ... 510(k) premarket notification with the U.S. Food and Drug ... product candidate. Excellagen XL is an ... customized collagen-based topical gel designed for use by physicians ...
... and LONDON, Nov. 2 A study from Thomson Reuters ... far outpacing research activity in the rest of the world. ... within the next decade. , The study, Global ... collaboration potential of China and its current place in world ...
... Pharmasset, Inc. (Nasdaq: VRUS ) today announced that it ... the Study of Liver Diseases (AASLD) on Monday, November 2, ... review Pharmasset,s progress on the programs that are the subject ... of this event via the internet, log on to the ...
Cached Biology Technology:Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 3Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 4China's Research Output More Than Doubled Since 2004, Thomson Reuters Study Reveals 2Pharmasset to Webcast an Investor Event from the AASLD Meeting 2Pharmasset to Webcast an Investor Event from the AASLD Meeting 3Pharmasset to Webcast an Investor Event from the AASLD Meeting 4
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
(Date:10/15/2014)... book ,Models of Life, is a non-traditional biophysics textbook ... The book is a journey of discovery into biological ... life and biological regulation. It is about how our ... communication between the billions of cells in an organism. ... relationships between principles, which can be found on both ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... growing mobile commerce market releases photos and video of the recent ... October 13 th . Gino Pereira , ... angel investor Mr. Chad A. Verdi rang the bell.  ... his investors and employees "for their work and dedication in bringing ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2New book about life as seen from physics 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... linked a chemical that plays an essential role in ... infertility, the 22nd annual conference of the European Society ... Amiri, embryology laboratory director at the IVF Centre, Fatemieh ... (NO) has been recognised as a molecule that plays ...
... at the Case Western Reserve University School of ... the brain's immune cells triggers a cascade of ... eventually leads to the neural cell death found ... findings in the Journal of Biological Chemistry article, ...
... live or die depends on whether they can muscle their ... Salk Institute for Biological Studies pin-pointed the molecular survival gear ... fray and hook up with other cells. , In ... in the lab of Fred H. Gage, Ph.D., a professor ...
Cached Biology News:Study links high levels of nitric oxide to infertility and sperm DNA damage 2Case Western Reserve University researchers find protein associated with brain cell death 2Life and death in the hippocampus: what young neurons need to survive 2Life and death in the hippocampus: what young neurons need to survive 3
QPRT Antibody...
This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
Agarose, Biotechnology grade, 500g...
... covering tissue sections and cell preparations immunohistochemically stained ... end products. UltraMount Plus can be ... AEC that require an aqueous mounting medium, or ... heating is required prior to use. This product ...
Biology Products: